Universal Health Services Reports Q3 Revenue Growth, $5.22 Diluted EPS

Universal Health Services reported Q3 2026 revenue of $4.73B, up 5.3% YoY, and net income of $308.7M. Diluted EPS was $5.22. Nine-month revenue grew 7.7% to $13.87B. The company completed its acquisition of Talkspace in August 2026.

Original reporting
Published Oct 27, 2026, 9:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 9:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Universal Health Services Reports Q3 Revenue Growth, $5.22 Diluted EPS — source image
Decision brief

The 30-second read

$UHSNeutralMed
01

Why it matters

The earnings beat on revenue but miss on operating income may lead to a muted market reaction, with investors focusing on margin trends and the Talkspace integration.

02

Market read

UHS earnings provide fresh data for healthcare sector investors; the mixed results could influence short‑term trading strategies.

03

What to watch

Acquisition of Talkspace may introduce integration risk and affect future earnings quality.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

The article summarizes Universal Health Services' Q3 2026 earnings release filed via an SEC 8‑K, highlighting revenue, earnings, and recent acquisition.

Company-level read

Ticker impact

$UHSNeutralHigh confidence
Context

Universal Health Services disclosed Q3 2026 revenue of $4.73B and EPS of $5.22 in its 8‑K filing.

Expected impact

likely modest pressure as investors weigh higher revenue against lower operating income

Evidence & confidence

Revenue beat suggests growth, but declining operating income could temper upside, leading to a sideways to slightly down reaction.

Market effects

Healthcare services sector may see modest uplift from UHS revenue growth, but profit margin concerns could limit broader impact.

UHS is a U.S. provider; impact confined to U.S. healthcare equities.

Limited, as the news pertains to a single U.S. company without global macro implications.

Counterpoint

Investors could short UHS if they believe operating margin compression signals deeper operational issues.

Key entities

  • Universal Health Services

    U.S. healthcare services provider (ticker UHS).

Related articles

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.

$CNCMed

Health insurers, hospitals rally after sweeping midterm win for Democrats

Shares of Medicaid-focused health insurers (Centene, Elevance, Molina) and hospital operators (HCA, Tenet, Universal) rose after Democrats won the midterms, raising hopes for sector-friendly policies. Analysts expect delays in Trump's OBBBA, easing pressure on Medicaid and ACA insurers, and potential extensions of enhanced subsidies. Year-to-date gains vary among companies.

$UHSHighAI 8/10

Softer surgery volumes, hospital woes dampened UHS’ Q3 earnings

Universal Health Services (UHS) lowered its 2026 earnings expectations due to declining surgeries and struggles at some hospitals. Q3 net income fell 17% to $308M, while revenues rose 5% to $4.7B. Challenges include lower surgery volumes, delays in new hospital profitability, and rising uninsured patients. UHS expects to be at the lower end of its guidance range for 2024.

$UHSMed

Guggenheim cuts Universal Health Services stock price target to $201 on weak Q3

Guggenheim reduced its price target for Universal Health Services (UHS) to $201 from $209, citing weak Q3 2026 EBITDA and macro pressures. UHS stock is down 8.5% in a week. The company lowered its 2026 EBITDA guidance but sees potential upside from expansions. UHS reported Q3 EPS of $5.22 and revenue of $4.73B, slightly beating estimates. Raymond James kept a Market Perform rating, noting softer profit trends and a cautious 2027 outlook.